Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor | Faculty of Business | en_US |
| dc.creator | Tang, Xiaojiao | - |
| dc.identifier.uri | https://theses.lib.polyu.edu.hk/handle/200/13454 | - |
| dc.language | English | en_US |
| dc.publisher | Hong Kong Polytechnic University | en_US |
| dc.rights | All rights reserved | en_US |
| dc.title | Innovation capability : key driver which influence the IPO performance of biotech companies in Hong Kong and mainland China | en_US |
| dcterms.abstract | Since 2018, the Hong Kong Stock Exchange and the Shanghai Stock Exchange have allowed biotechnology companies without revenue or profits to list, providing these companies with favorable financing conditions. Coinciding with the outbreak of the COVID-19 pandemic, this sector experienced a boom period. However, as the pandemic has subsided, these companies have been slow to generate revenue, diminishing patience among capital market participants and poor performance in the secondary market. Given the underperformance of these companies post-initial public offering (IPO) and inspired by the development trajectory of the biotechnology sector in U.S. stock markets, this study focuses on the characteristics of biotechnology companies. | en_US |
| dcterms.abstract | Innovation capability is the most crucial factor influencing the IPO pricing and post-IPO performance of biotechnology companies. In this study, the number of R&D personnel (RDP), R&D expenditures, and pipeline quantity are used to measure innovation capability and further explore the relationships between innovation capability and first-day returns and between innovation capability and three-year abnormal returns post-IPO. The findings show that the number of RDP is negatively correlated with first-day returns, whereas the R&D expenditure is positively correlated with three-year abnormal returns post-IPO. These findings highlight the correlation between innovation capability and the IPO performance of biotechnology companies, revealing key considerations in pricing strategies for biotechnology firms that lack both revenue and profits. | en_US |
| dcterms.extent | 96 pages | en_US |
| dcterms.isPartOf | PolyU Electronic Theses | en_US |
| dcterms.issued | 2024 | en_US |
| dcterms.educationalLevel | D.B.A. | en_US |
| dcterms.educationalLevel | All Doctorate | en_US |
| dcterms.LCSH | Biotechnology industries | en_US |
| dcterms.LCSH | Going public (Securities) | en_US |
| dcterms.LCSH | Hong Kong Polytechnic University -- Dissertations | en_US |
| dcterms.accessRights | restricted access | en_US |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| 7923.pdf | For All Users (off-campus access for PolyU Staff & Students only) | 743.02 kB | Adobe PDF | View/Open |
Copyright Undertaking
As a bona fide Library user, I declare that:
- I will abide by the rules and legal ordinances governing copyright regarding the use of the Database.
- I will use the Database for the purpose of my research or private study only and not for circulation or further reproduction or any other purpose.
- I agree to indemnify and hold the University harmless from and against any loss, damage, cost, liability or expenses arising from copyright infringement or unauthorized usage.
By downloading any item(s) listed above, you acknowledge that you have read and understood the copyright undertaking as stated above, and agree to be bound by all of its terms.
Please use this identifier to cite or link to this item:
https://theses.lib.polyu.edu.hk/handle/200/13454